Total Payments
$5,877
2024 Payments
$3,450
Companies
18
Transactions
47
Payment Breakdown by Category
Food & Beverage$2,722 (46.3%)
Travel$1,641 (27.9%)
Research$1,513 (25.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,722 | 27 | 46.3% |
| Travel and Lodging | $1,641 | 8 | 27.9% |
| Unspecified | $1,513 | 12 | 25.8% |
Payments by Type
General
$4,363
35 transactions
Research
$1,513
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,283 | 16 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,513 | 12 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $233.08 | 2 | $0 (2023) |
| Paratek Pharmaceuticals, Inc. | $226.49 | 2 | $0 (2023) |
| ABBVIE INC. | $172.12 | 2 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $131.09 | 1 | $0 (2024) |
| Grifols USA, LLC | $125.00 | 1 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $124.97 | 1 | $0 (2024) |
| GENZYME CORPORATION | $122.32 | 1 | $0 (2022) |
| Axsome Therapeutics, Inc. | $121.86 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,450 | 26 | Regeneron Pharmaceuticals, Inc. ($1,513) |
| 2023 | $1,757 | 14 | Merck Sharp & Dohme LLC ($1,058) |
| 2022 | $592.70 | 6 | ABBVIE INC. ($172.12) |
| 2021 | $77.10 | 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($77.10) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $426.71 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $233.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $117.51 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $117.51 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $396.46 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $124.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $123.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $60.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $60.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $50.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $47.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $24.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $24.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $24.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/11/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $479.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/11/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $102.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/15/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $110.96 | General |
| 06/13/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: SCHIZOPHRENIA | ||||||
| 05/16/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $131.09 | General |
| Category: Central Nervous System | ||||||
| 04/19/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $107.28 | General |
| 03/28/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $112.46 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma | Regeneron Pharmaceuticals, Inc. | $1,513 | 12 |
About Patricia Lopez
Patricia Lopez is a Family healthcare provider based in Kissimmee, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2018. The National Provider Identifier (NPI) number assigned to this provider is 1215409735.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Patricia Lopez has received a total of $5,877 in payments from pharmaceutical and medical device companies, with $3,450 received in 2024. These payments were reported across 47 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($2,722).
Ad
Practice Information
- Specialty Family
- Location Kissimmee, FL
- Active Since 12/21/2018
- Last Updated 12/21/2018
- Taxonomy Code 363LF0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215409735
Products in Payments
- DUPIXENT (Biological) $1,513
- INGREZZA (Drug) $233.08
- NUZYRA (Drug) $226.49
- Austedo XR (Drug) $131.09
- Prolastin-C Liquid (Biological) $125.00
- FANAPT (Drug) $124.97
- FABRAZYME (Biological) $122.32
- Auvelity (Drug) $121.86
- QUVIVIQ (Drug) $121.30
- AIRSUPRA (Drug) $112.46
- LEQVIO (Drug) $106.37
- KRYSTEXXA (Biological) $101.20
- UBRELVY (Drug) $88.53
- INVEGA SUSTENNA (Drug) $87.00
- VRAYLAR (Drug) $83.59
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Kissimmee
Roger Rivera, Dnp, DNP
Family — Payments: $1.1M
Family $1.1M
Mrs. Reena Varghese, Arnp, ARNP
Family — Payments: $16,376
Family $16,376
Dr. Trinese Hardy, Drph, Pmhnp, Fnp, DRPH, PMHNP, FNP
Family — Payments: $12,076
Family $12,076
Marie Adolphe, Arnp, ARNP
Family — Payments: $8,279
Family $8,279
Mailen Broche, Aprn, APRN
Family — Payments: $6,558
Family $6,558
Mrs. Marilyn Velez, Arnp, ARNP
Family — Payments: $5,635
Family $5,635